News - For over 20 years now, Professor Simard has been working on genetic susceptibility to breast cancer. These latest research findings helped identify 49 new genetic variations involved in the risk of developing this disease, almost tripling the number of variations now known. In the vast majority of breast cancer cases affecting the general population, it is the interaction between these genetic variations and other environmental and lifestyle factors that is involved in the development of the disease.
News - This focused partnering event will showcase cutting edge cancer R&D activities in six regions and clusters. Massachusetts, Quebec, Toulouse, Oslo, the UK "Golden triangle" and the Chicago Cancer Cluster have teamed up to present their innovative oncology pipelines to an international audience as a satellite event to BIO 2013. The compact event features company and poster presentations and focused networking opportunities with an international oncology community.
News - DiagnoCure is pleased to report that Dr. Harry Rittenhouse spoke about the clinical utility of the urinary marker PCA3 during the International Conference on Prostate Cancer Prevention 2013 with Consensus Conference on Chemoprevention of Prostate Cancer held during the 28th annual European Association of Urology congress held in Milan from March 15-19th.
News - This morning, the Canadian Cancer Society (CCS) announced that it will grant $2.3 million to researchers in Montreal and Quebec City who are aiming to develop cancer vaccines. This includes Dr Yves Fradet’s team at Université Laval aims to apply this approach to bladder cancer. In 2012, this disease affected 7,800 people in Canada and 2,740 people in Quebec.
News - Aeterna Zentaris announces that a first patient has been treated for the randomized Phase 2 trial in chemotherapy refractory triple-negative luteinizing hormone-releasing hormone receptor-positive metastatic breast cancer, with the Company's targeted doxorubicin peptide conjugate, AEZS 108.
News - Based on the findings of this Best Practices research, Frost & Sullivan is proud to present the 2013 North American Entrepreneurial Company of the Year Award in the Molecular Diagnostics Market to GenePOC Inc, Quebec City, Canada. Frost & Sullivan is in its 50th year in business with a global research organization of 1,800 analysts and consultants who monitor more than 300 industries and 250,000 companies.
News - The main goal of this program is to support unconventional and highly innovative projects that could lead to the development of cutting edge tools or technologies addressing critical needs in drug discovery or development. This competition is widely open to the Quebec scientific community including private organizations and academic research institutions.
News - CQDM is pleased to announce the renewal of its funding from the Business-led Networks of Centres of Excellence (BL-NCE) for a total amount of $ 11.7 M. For more information, please consult the press release and picture enclosed.
News - Medicago announces that Investissement Québec has agreed to a three year extension of the maturity date of its 2003 loan made under the BioLevier program. Originally, the maturity date of the loan in the principal amount of $15.3M, was December 31, 2014 and is now December 31, 2017.
News - Medicago announces the execution of a collaboration agreement with Mitsubishi Chemical Holdings Corporation to develop a next generation technology for plant production. The objectives of the collaboration are to evaluate MCHC's Plant Factory System, a closed cultivation system, to produce Nicotiana Benthamiana plants for protein production using Medicago's technologies.